Gerald Mayer Rubin (born 1950) is an American biologist, notable for pioneering the use of transposable P elements in genetics, and for leading the public project to sequence the Drosophila melanogaster genome. Related to his genomics work, Rubin's lab is notable for development of genetic and genomics tools and studies of signal transduction and gene regulation. Rubin also serves as a vice president of the Howard Hughes Medical Institute and executive director of the Janelia Research Campus.^[2][3][4][5]

Rubin was born in Boston, Massachusetts, in 1950, attending the Boston Latin School. Rubin completed his undergraduate degree in biology at MIT, working at Cold Spring Harbor Laboratory during the summer.^[6][7] He completed his Ph.D. at the University of Cambridge,^[8] working at the Laboratory of Molecular Biology in 1974,^[9] for studies on 5.8S ribosomal RNA supervised by Sydney Brenner.^[8]

Following his PhD, Rubin did postdoctoral research at Stanford University with David Hogness.^[10]

Rubin's first faculty position was at Harvard Medical School, followed by the Carnegie Institution of Washington; in 1983 he accepted an appointment as the John D. MacArthur Professor of Genetics at the University of California, Berkeley. He was appointed a Howard Hughes Medical Investigator in 1987. He is currently the MacArthur Professor of Genetics emeritus, Genomics and Development, in Berkeley's Department of Molecular and Cell Biology.

Rubin has taken a leading role in a number of high-profile scientific research projects.^{[11][12][13][14][15][16][17][18][19][20][21][excessive citations]} As the director of the Berkeley Drosophila Genome Project, he led the public effort to sequence Drosophila melanogaster.^[17] As Vice President of the Howard Hughes Medical Institute, Rubin led the development of HHMI's Janelia Research Campus, an independent biomedical research institute in Virginia.^[6]

His lab is particularly known for its development of genomics tools, studies of gene regulation, and other genome-wide research.

He was one of the three scientific founders of Exelixis in 1994; the company's original business plan was to exploit genomic research in Drosophila and other model organism to discover biological targets that could be used in drug discovery.^[22]